Edwards Lifesciences Corp. (($EW)) announced an update on their ongoing clinical study. Study Overview: Edwards Lifesciences Corp. is conducting ...

The data are largely in line with those seen at 5 years, but the follow-up reassures there’s no concern about valve ...

Edwards Lifesciences (NYSE: EW) today announced new data demonstrating long-term benefits with its Sapien heart valve system.

Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data, which showed superior clinical ...

Investing.com -- Edwards Lifesciences (NYSE:EW) stock rose 4.5% following the presentation of new data showing long-term benefits and valve performance of its SAPIEN 3 TAVR.

Edwards Lifesciences Corp. (($EW)) announced an update on their ongoing clinical study. Edwards Lifesciences Corp. is collaborating with World ...

Strong TAVR demand and expanding valve therapies are set to power EW's Q3 results despite lower EPS estimates.

Edwards Lifesciences remains a market leader in transcatheter heart valve technologies, with strong secular tailwinds and ...

Edwards Lifesciences (NYSE: EW) welcomes the updated ESC/EACTS guidelines for valvular heart disease, which establish a simplified care pathway for all severe aortic stenosis (AS) patients, regardless ...

The Sapien 3 Ultra Resilia transcatheter aortic valve replacement system. [Image courtesy of Edwards Lifesciences] BTIG analysts have upgraded Edwards Lifesciences (NYSE: EW) + to “Buy” with TAVR on ...

“We are pleased to report strong second quarter results that delivered double-digit sales growth. Based on our better-than-expected first half performance and the many catalysts across our portfolio, ...